Bis-halogen-anthraniloyl-substituted nucleoside 5'-triphosphates as potent and selective inhibitors of Bordetella pertussis adenylyl cyclase toxin

Journal of Pharmacology and Experimental Therapeutics

Volumn 336, Issue 1, 2011, Pages 104-115

  Geduhn, Jens ^a   Dove, Stefan ^b   Shen, Yuequan ^c,d   Tang, Wei Jen ^e   König, Burkhard ^a   Seifert, Roland ^f  

^a Institute of Clinical Chemistry   (Germany)

^b Department of Pharmaceutical and Medicinal Chemistry II ^*  (Germany)

^c UNIVERSITY OF REGENSBURG   (Germany)

^d NANKAI UNIVERSITY   (China)

^e UNIVERSITY OF CHICAGO   (United States)

^f HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; ADENYLATE CYCLASE INHIBITOR; BIS ANTHRANILOYL DERIVATIVE; CALMODULIN; NUCLEOSIDE TRIPHOSPHATE; UNCLASSIFIED DRUG;

ARTICLE; BORDETELLA PERTUSSIS; CATALYSIS; DRUG BINDING; DRUG POTENCY; MOLECULAR MODEL; PRIORITY JOURNAL; SIGNAL NOISE RATIO; STRUCTURE ACTIVITY RELATION;

ADENOSINE TRIPHOSPHATE; ADENYLATE CYCLASE; ANIMALS; ANTHRANILIC ACIDS; BINDING SITES; BORDETELLA PERTUSSIS; CELL LINE; HALOGENS; PERTUSSIS TOXIN; SPODOPTERA; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 78650778440     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.174219     Document Type: Article

References (31)

1. Bessay EP, Blount MA, Zoraghi R, Beasley A, Grimes KA, Francis SH, and Corbin JD (2008) Phosphorylation increases affinity of the phosphodiesterase-5 catalytic site for tadalafil. J Pharmacol Exp Ther 325:62-68.
2. Carbonetti NH (2010) Pertussis toxin and adenylate cyclase toxin: key virulence factors of Bordetella pertussis and cell biology tools. Future Microbiol 5:455-469.
3. Clark M, Cramer RD III, and Van Opdenbosch N (1989) Validation of the general purpose Tripos 5.2 force field. J Comput Chem 10:982-1012.
4. Cornell WD, Cieplak P, Bayly CI, Gould IR, Merz KMJ, Ferguson DM, Spellmeyer DC, Fox T, Caldwell JW, and Kollman PA (1995) A second generation force field for the simulation of proteins and nucleic acids. J Am Chem Soc 117:5179-5197.
5. Crowcroft NS and Pebody RG (2006) Recent developments in pertussis. Lancet 367:1926-1936.
6. Ghose AK, Viswanadhan VN, and Wendoloski J (1998) Prediction of hydrophobic (lipophilic) properties of small organic molecules using fragmental methods: an analysis of ALOGP and CLOGP. J Phys Chem A 102:3762-3772.
7. Gille A and Seifert R (2003) 2'(3')-O-(N-methylanthraniloyl)-substituted GTP analogs: a novel class of potent competitive adenylyl cyclase inhibitors. J Biol Chem 278:12672-12679.
8. Gille A, Lushington GH, Mou TC, Doughty MB, Johnson RA, and Seifert R (2004) Differential inhibition of adenylyl cyclase isoforms and soluble guanylyl cyclase by purine and pyrimidine nucleotides. J Biol Chem 279:19955-19969.
9. Göttle M, Dove S, Kees F, Schlossmann J, Geduhn J, König B, Shen Y, Tang WJ, Kaever V, and Seifert R (2010) Cytidylyl and uridylyl cyclase activity of Bacillus anthracis edema factor and Bordetella pertussis CyaA. Biochemistry 49:5494-5503.
10. Göttle M, Dove S, Steindel P, Shen Y, Tang WJ, Geduhn J, König B, and Seifert R (2007) Molecular analysis of the interaction of Bordetella pertussis adenylyl cyclase with fluorescent nucleotides. Mol Pharmacol 72:526-535.
11. Göttle M, Geduhn J, König B, Gille A, Höcherl K, and Seifert R (2009) Characterization of mouse heart adenylyl cyclase. J Pharmacol Exp Ther 329:1156-1165.
12. Guiso N (2009) Bordetella pertussis and pertussis vaccines. Clin Infect Dis 49:1565-1569.
13. Guo Q, Shen Y, Lee YS, Gibbs CS, Mrksich M, and Tang WJ (2005) Structural basis for the interaction of Bordetella pertussis adenylyl cyclase toxin with calmodulin. EMBO J 24:3190-3201.
14. Heiden W, Moeckel G, and Brickmann J (1993) A new approach to analysis and display of local lipophilicity/hydrophilicity mapped on molecular surfaces. J Comput Aided Mol Des 7:503-514.
15. Hiratsuka T (1983) New ribose-modified fluorescent analogs of adenine and guanine nucleotides available as substrates for various enzymes. Biochim Biophys Acta 742:496-508.
16. Jameson DM and Eccleston JF (1997) Fluorescent nucleotide analogs: synthesis and applications. Methods Enzymol 278:363-390.
17. Johnson RA and Shoshani I (1990) Inhibition of Bordetella pertussis and Bacillus anthracis adenylyl cyclases by polyadenylate and "P"-site agonists. J Biol Chem 265:19035-19039.
18. Ladant D and Ullmann A (1999) Bordetella pertussis adenylate cyclase: a toxin with multiple talents. Trends Microbiol 7:172-176.
19. Laux WH, Pande P, Shoshani I, Gao J, Boudou-Vivet V, Gosselin G, and Johnson RA (2004) Pro-nucleotide inhibitors of adenylyl cyclases in intact cells. J Biol Chem 279:13317-13332.
20. Linder JU and Schultz JE (2008) Versatility of signal transduction encoded in dimeric adenylyl cyclases. Curr Opin Struct Biol 18:667-672.
21. Mou TC, Gille A, Fancy DA, Seifert R, and Sprang SR (2005) Structural basis for the inhibition of mammalian membrane adenylyl cyclase by 2'(3')-O-(N-methylanthraniloyl)-guanosine 5'-triphosphate. J Biol Chem 280:7253-7261.
22. Mou TC, Gille A, Suryanarayana S, Richter M, Seifert R, and Sprang SR (2006) Broad specificity of mammalian adenylyl cyclase for interaction with 2',3'- substituted purine- and pyrimidine nucleotide inhibitors. Mol Pharmacol 70:878-886.
23. Ni Q, Shaffer J, and Adams JA (2000) Insights into nucleotide binding in protein kinase A using fluorescent adenosine derivatives. Protein Sci 9:1818-1827.
24. Rensland H, Lautwein A, Wittinghofer A, and Goody RS (1991) Is there a ratelimiting step before GTP cleavage by H-ras p21? Biochemistry 30:11181-11185.
25. Shen Y, Lee YS, Soelaiman S, Bergson P, Lu D, Chen A, Beckingham K, Grabarek Z, Mrksich M, and Tang WJ (2002) Physiological calcium concentrations regulate calmodulin binding and catalysis of adenylyl cyclase exotoxins. EMBO J 21:6721-6732.
26. Soelaiman S, Wei BQ, Bergson P, Lee YS, Shen Y, Mrksich M, Shoichet BK, and Tang WJ (2003) Structure-based inhibitor discovery against adenylyl cyclase toxins from pathogenic bacteria that cause anthrax and whooping cough. J Biol Chem 278:25990-25997.
27. Suryanarayana S, Wang JL, Richter M, Shen Y, Tang WJ, Lushington GH, and Seifert R (2009) Distinct interactions of 2'- and 3'-O-(N-methyl) anthraniloylisomers of ATP and GTP with the adenylyl cyclase toxin from Bacillus anthracis, edema factor. Biochem Pharmacol 78:224-230.
28. Taha HM, Schmidt J, Göttle M, Suryanarayana S, Shen Y, Tang WJ, Gille A, Geduhn J, König B, Dove S, et al. (2009) Molecular analysis of the interaction of anthrax adenylyl cyclase toxin, edema factor, with 2'(3')-O-(N-methyl)anthraniloyl)-substituted purine and pyrimidine nucleotides. Mol Pharmacol 75:693-703.
29. Tesmer JJ, Dessauer CW, Sunahara RK, Murray LD, Johnson RA, Gilman AG, and Sprang SR (2000) Molecular basis for P-site inhibition of adenylyl cyclase. Biochemistry 39:14464-14471.
30. Vojtova J, Kamanova J, and Sebo P (2006) Bordetella adenylate cyclase toxin: a swift saboteur of host defense. Curr Opin Microbiol 9:69-75.
31. Yahr TL, Vallis AJ, Hancock MK, Barbieri JT, and Frank DW (1998) ExoY, an adenylate cyclase secreted by the Pseudomonas aeruginosa type III system. Proc Natl Acad Sci USA 95:13899-14904.